Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
147 hedge funds and large institutions have $358M invested in Clovis Oncology, Inc. in 2019 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 36 increasing their positions, 50 reducing their positions, and 41 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
79% more capital invested
Capital invested by funds: $200M → $358M (+$158M)
3% less call options, than puts
Call options by funds: $114M | Put options by funds: $118M
4% less funds holding
Funds holding: 153 → 147 (-6)
12% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 41
28% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$19.4M |
| 2 |
PA
Pinnacle Associates
New York
|
+$4.57M |
| 3 |
AG
Artal Group
Luxembourg
|
+$3.64M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$2.44M |
| 5 |
Jane Street
New York
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECP
Elk Creek Partners
Denver,
Colorado
|
-$18.2M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$14.2M |
| 3 |
Morgan Stanley
New York
|
-$11M |
| 4 |
BlackRock
New York
|
-$10.6M |
| 5 |
D.E. Shaw & Co
New York
|
-$9.71M |
CLVS Hedge Fund Activity: Q4 2019 in Review
147 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2019, worth a combined $358M — up 79% from $200M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of CLVS and 36 opened new positions — a net loss of 5 holders — while 50 trimmed existing stakes and 36 added.
The largest buyer was State Street, adding an estimated $19.4M. The largest seller was Elk Creek Partners, cutting an estimated $18.2M.
- 147 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2019, down from 153 in Q3 2019.
- Funds reported $358M of Clovis Oncology, Inc. stock for Q4 2019, up 79% quarter-over-quarter.
- 36 funds opened new Clovis Oncology, Inc. positions in Q4 2019 and 41 closed out, a net change of -5 holders.
- The largest Clovis Oncology, Inc. buyer in Q4 2019 was State Street, an estimated $19.4M added.
- The largest Clovis Oncology, Inc. seller in Q4 2019 was Elk Creek Partners, an estimated $18.2M sold.
Based on aggregated 13F filings for Q4 2019.